Please use this identifier to cite or link to this item:
Title: Partial IGF-1 deficiency is sufficient to reduce heart contractibility, angiotensin II sensibility, and alter gene expression of structural and functional cardiac proteins.
Authors: González-Guerra, José Luis
Castilla-Cortazar, Inma
Aguirre, Gabriel A
Muñoz, Úrsula
Martín-Estal, Irene
Ávila-Gallego, Elena
Granado, Miriam
Puche, Juan E
García-Villalón, Ángel Luis
metadata.dc.subject.mesh: Angiotensin II
Body Weight
Extracellular Matrix
Gene Expression Regulation
Insulin-Like Growth Factor I
Mice, Transgenic
Myocardial Contraction
Organ Size
Real-Time Polymerase Chain Reaction
Issue Date: 14-Aug-2017
Abstract: Circulating levels of IGF-1 may decrease under several circumstances like ageing, metabolic syndrome, and advanced cirrhosis. This reduction is associated with insulin resistance, dyslipidemia, progression to type 2 diabetes, and increased risk for cardiovascular diseases. However, underlying mechanisms between IGF-1 deficiency and cardiovascular disease remain elusive. The specific aim of the present work was to study whether the partial IGF-1 deficiency influences heart and/or coronary circulation, comparing vasoactive factors before and after of ischemia-reperfusion (I/R). In addition, histology of the heart was performed together with cardiac gene expression for proteins involved in structure and function (extracellular matrix, contractile proteins, active peptides); carried out using microarrays, followed by RT-qPCR confirmation of the three experimental groups. IGF-1 partial deficiency is associated to a reduction in contractility and angiotensin II sensitivity, interstitial fibrosis as well as altered expression pattern of genes involved in extracellular matrix proteins, calcium dynamics, and cardiac structure and function. Although this work is descriptive, it provides a clear insight of the impact that partial IGF-1 deficiency on the heart and establishes this experimental model as suitable for studying cardiac disease mechanisms and exploring therapeutic options for patients under IGF-1 deficiency conditions.
metadata.dc.identifier.doi: 10.1371/journal.pone.0181760
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC5555709.pdf11,32 MBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons